Skip Navigation

Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: Analysis of Phase 3 ASTRAL trials

  1. Jordan J. Feld9
  1. 1The Kirby Institute, UNSW Australia, Sydney, NSW, Australia
  2. 2Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany
  3. 3Portsmouth Hospitals NHS Trust, Portsmouth, UK
  4. 4Brownlee Centre, Glasgow, UK
  5. 5Gilead Sciences, Inc., Foster City, California, USA
  6. 6Queen Mary University London, London, UK
  7. 7Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy
  8. 8Johns Hopkins University, Baltimore, Maryland, USA
  9. 9Toronto Centre for Liver Disease, Toronto, Ontario, Canada
  1. Corresponding author: Jason Grebely, PhD, Associate Professor, Viral Hepatitis Clinical Research Program, The Kirby Institute, UNSW Australia. Phone: +61-2-9385 0957, Fax: +61-2-9385 0876, email: jgrebely{at}
  1. Alternate corresponding author: Jordan J Feld, MD, Assistant Professor, Toronto Centre for Liver Disease, Toronto, Ontario, Canada. Phone: +1-416 603 6230, Fax: +1-416 603 5472, email: jordan.feld{at}


In this post-hoc analysis of the Phase 3 ASTRAL trials [non-opioid substitution therapy (OST), n=984; OST, n=51] evaluating the once-daily, pan-genotypic regimen of sofosbuvir/velpatasvir for HCV infection, OST did not impact completion, adherence, sustained virologic response (SVR12), or safety. SVR12 was 96% (95% CI 87%, >99%) in those receiving OST.


Published on behalf of

cid cover HIV Medicine Association Logo

Society Members: For your free access to this journal, log in via the IDSA members area.

Impact Factor: 8.886

5-Yr impact factor: 9.206

For Reviewers

Looking for your next opportunity?

Looking for jobs...

For the Media

Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.